Getting the Most Out of CAR-T Bioprocessing

CAR-T cell therapy is among the most promising treatments being developed for hematological cancers. Although the engineered T cells used in the approach uniquely target a patient’s cancer cells, their quality varies widely between batches and patients. Minimizing hands on involvement in CAR-T cell development reduces some sources of this variation, and automation technology that processes cell products and evaluates their functions helps achieve this. Automation also reduces the risk for cell contamination, potentially facilitating both cell development and translation to clinical approval.

Download this technical note from IsoPlexis to learn more about

• Applications of automated single-cell functional characterization and single cell quality
• Protocols that minimize impact on live cells
• Guidelines for the most commonly used cell types and applications
• Characterizing CAR-T cell products after T-cell enrichment, activation, viral transduction, expansion, and harvest for downstream use